Sun BioPharma Inc. is a clinical-stage bio-pharmaceutical company developing disruptive therapeutics for significant unmet medical needs. The Company's initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis. The Company has completed enrollment in its first-in-human Phase 1a clinical safety trial of SBP-101, in the treatment of previously treated pancreatic cancer patients. The trial established a safe and well tolerated dose. The Company anticipates initiation of patient enrollment in its next clinical trial in the first quarter of 2018 which will be a Phase 1a/1b study of the safety and efficacy of SBP-101 administered in combination with gemcitabine and nab-paclitaxel. Sun BioPharma has scientific collaborations with pancreatic disease experts the Mayo Clinic Scottsdale and Cedars Sinai Medical Center in the US, the University of Miami, the Austin Health Cancer Trials Centre and the Ashford Cancer Centre in Australia. SBP-101 is a novel small-molecule synthetic polyamine compound designed to exert therapeutic effects in a mechanism of action specific to the pancreas. SBP-101 has been shown to be highly effective in several human pancreatic cancer models, demonstrating superior activity to existing chemotherapy agents. Combination potential has also been shown for pancreatic cancer. SBP-101 is expected to hold an edge over current pancreatic cancer therapies, as it specifically targets the exocrine pancreas.